Sugi Predict

Sugi Predict / Targets / PIK3CG

PIK3CG

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform · P48736 · PIK3CG on Sugi Atlas →

267,816 patent compounds predicted against PIK3CG, 156,860 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3CG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive PHASE2COMPLETED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer PHASE2COMPLETED
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 PHASE2NOT_YET_RECRUITING
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules PHASE1COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PIK3CG binder may also engage these)

ProteinNameSimilarity
O02697 — 1.000 O02697 →
Q9JHG7 — 1.000 Q9JHG7 →
Q8BTI9 — 1.000 Q8BTI9 →
A0A0G2K344 — 0.997 A0A0G2K344 →
Q9Z1L0 — 0.996 Q9Z1L0 →
PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.996 landscape →
P32871 — 0.995 P32871 →
P42337 — 0.994 P42337 →
PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 0.994 landscape →
PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 0.993 landscape →
P42348 — 0.991 P42348 →
Q5D891 — 0.991 Q5D891 →
Q6AZN6 — 0.991 Q6AZN6 →
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 0.990 landscape →
O88763 — 0.988 O88763 →
B2RXC1 — 0.988 B2RXC1 →
Q6PF93 — 0.988 Q6PF93 →
Q7Z392 — 0.988 Q7Z392 →
P42339 — 0.988 P42339 →
O35904 — 0.987 O35904 →
P0CI65 — 0.986 P0CI65 →
A2AF47 — 0.986 A2AF47 →
Q66K14 — 0.986 Q66K14 →
USP7 Ubiquitin carboxyl-terminal hydrolase 7 0.986 landscape →
A6N6J5 — 0.986 A6N6J5 →
Q6PJI9 — 0.985 Q6PJI9 →
PTK2 Focal adhesion kinase 1 0.985 landscape →
Q803R5 — 0.985 Q803R5 →
Q8VDY4 — 0.985 Q8VDY4 →
Q5ZJM3 — 0.985 Q5ZJM3 →